Literature DB >> 9283714

Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.

H C Jackson1, A M Needham, L J Hutchins, S E Mazurkiewicz, D J Heal.   

Abstract

1. The effects of the potent 5-hydroxytryptamine (5-HT) and noradrenaline reuptake inhibitor (serotonin-noradrenaline reuptake inhibitor, SNRI), sibutramine, on the cumulative food intake of freely-feeding male Sprague-Dawley rats during an 8 h dark period were investigated and compared to those of the selective 5-HT reuptake inhibitor (selective serotonin reuptake inhibitor, SSRI), fluoxetine; the selective noradrenaline reuptake inhibitor, nisoxetine; the 5-HT and noradrenaline reuptake inhibitors, venlafaxine and duloxetine; and the 5-HT releaser and 5-HT reuptake inhibitor, (+)-fenfluramine. 2. Sibutramine (3 and 10 mg kg-1, p.o.) and (+)-fenfluramine (1 and 3 mg kg-1, p.o.) produced a significant, dose-dependent decrease in food intake over the 8 h dark period. These responses became apparent within the first 2 h following drug administration. 3. Fluoxetine (3, 10 and 30 mg kg-1, p.o.), and nisoxetine (3, 10 and 30 mg kg-1, p.o.) had no significant effect on food intake during the 8 h dark period. However, a combination of fluoxetine and nisoxetine (30 mg kg-1, p.o., of each) significantly decreased food intake 2 and 8 h after drug administration. 4. Venlafaxine (100 and 300 mg kg-1, p.o.) and duloxetine (30 mg kg-1, p.o.) also significantly decreased food intake in the 2 and 8 h following drug administration. 5. The results of this study demonstrate that inhibition of 5-HT and noradrenaline reuptake by sibutramine, venlafaxine, duloxetine, or by a combination of fluoxetine and nisoxetine, markedly reduces food intake in freely-feeding rats and suggest that this may be a novel approach for the treatment of obesity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9283714      PMCID: PMC1564869          DOI: 10.1038/sj.bjp.0701312

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

Review 1.  Central nervous system biogenic amine targets for control of appetite and energy expenditure.

Authors:  David L Nelson; Donald R Gehlert
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

2.  From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.

Authors:  Sangwon F Kim; Alex S Huang; Adele M Snowman; Cory Teuscher; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

3.  Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats.

Authors:  G Grignaschi; E Fanelli; I Scagnol; R Samanin
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 4.  The utility of animal models to evaluate novel anti-obesity agents.

Authors:  Steven P Vickers; Helen C Jackson; Sharon C Cheetham
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y.

Authors:  M Brown; C Bing; P King; L Pickavance; D Heal; J Wilding
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

6.  Thermogenic effects of sibutramine and its metabolites.

Authors:  I P Connoley; Y L Liu; I Frost; I P Reckless; D J Heal; M J Stock
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

7.  Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation.

Authors:  David C Jewett; Thomas W Hahn; Travis R Smith; Britta L Fiksdal; Jason M Wiebelhaus; Andrew R Dunbar; Catherine R Filtz; Noah L Novinska; Allen S Levine
Journal:  Psychopharmacology (Berl)       Date:  2008-10-15       Impact factor: 4.530

Review 8.  Sibutramine. A review of its contribution to the management of obesity.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

9.  Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.

Authors:  Peter S Talbot; Stefan Bradley; Cyril P Clarke; Kola O Babalola; Andrew W Philipp; Gavin Brown; Adam W McMahon; Julian C Matthews
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

10.  Running wheel activity is sensitive to acute treatment with selective inhibitors for either serotonin or norepinephrine reuptake.

Authors:  Martin Weber; Sonja Talmon; Ilka Schulze; Christine Boeddinghaus; Gerhard Gross; Hans Schoemaker; Karsten M Wicke
Journal:  Psychopharmacology (Berl)       Date:  2008-12-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.